Scienture Holdings Inc
SCNX
查看详细走势图
0.571USD
+0.072+14.47%
收盘 12/19, 16:00（美东）报价延迟15分钟
13.20M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
+14.47%
5天
-5.76%
1月
+2.24%
6月
-37.40%
今年开始到现在
-90.57%
1年
-92.47%
查看详细走势图
TradingKey Scienture Holdings Inc股票评分
单位: USD 更新时间: 2025-12-19操作建议
Scienture Holdings Inc当前公司基本面数据相对健康，增长潜力很大。当前估值合理，在药品行业排名128/158位。机构持股占比非常高，中期看，股价处于下降通道。近一个月，市场表现较强，基本面评分较高，但较强的走势得没有得到技术面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Scienture Holdings Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
分析师目标
根据
0
位分析师
--
评级
0.000
目标均价
0.00%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Scienture Holdings Inc亮点
亮点风险
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
业绩增长期
公司处于发展阶段，最新年度总收入136.64K美元
业绩转盈
公司业绩转盈，最新年度盈利美元
估值高估
公司最新PE估值-0.07，处于3年历史高位
机构加仓
最新机构持股464.78K股，环比增加34.20%
先锋集团持仓
明星投资者先锋集团持仓，最新持仓市值157.02K
Scienture Holdings Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Scienture Holdings Inc简介
Scienture Holdings, Inc., through its wholly owned subsidiary, Scienture, LLC, is a specialty pharmaceutical company focused on providing enhanced value to patients, physicians and caregivers by offering specialty products to satisfy unmet market needs. Scienture, LLC is focused on developing and commercializing products for the treatment of central nervous system and cardiovascular diseases. Scienture LLC is developing a range of product candidates, including new potential treatments for hypertension, migraine, pain and thrombosis and other related disorders. The Company's product candidates include SCN- 102 (hypertension), SCN- 104 (CNS-Pain), SCN- 106 (Cardiovascular) and SCN- 107 (Pain). SCN-102 is an oral liquid formulation of losartan potassium in development for the treatment of hypertension. SCN-104 is a multi-dose pen-based delivery system for self-injection and increased patient convenience, which is in development for the acute treatment of migraine headaches.
公司代码SCNX
公司Scienture Holdings Inc
CEOHariharan (Shankar)
网址
常见问题
Scienture Holdings Inc(SCNX)的当前股价是多少？
Scienture Holdings Inc(SCNX)的当前股价是 0.571。
Scienture Holdings Inc的股票代码是什么？
Scienture Holdings Inc的股票代码是SCNX。
Scienture Holdings Inc股票的52周最高点是多少？
Scienture Holdings Inc股票的52周最高点是8.190。
Scienture Holdings Inc股票的52周最低点是多少？
Scienture Holdings Inc股票的52周最低点是0.461。
Scienture Holdings Inc的市值是多少？
Scienture Holdings Inc的市值是13.20M。
Scienture Holdings Inc的净利润是多少？
Scienture Holdings Inc的净利润为9.07M。
现在Scienture Holdings Inc(SCNX)的股票是买入、持有还是卖出？
根据分析师评级，Scienture Holdings Inc(SCNX)的总体评级为--，目标价格为--。
Scienture Holdings Inc(SCNX)股票的每股收益（EPS TTM）是多少
Scienture Holdings Inc(SCNX)股票的每股收益（EPS TTM）是-8.529。
相关品种
